Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036970 | 1.00 | CYP2C9 (0.45) | CYP2C9MEN1KMT2AASAH1PSMB5 | |
| SCHEMBL4341764 | 0.86 | MEN1 (0.38) | MEN1KMT2AASAH1CETPTHRB | |
| SCHEMBL15468359 | 0.83 | MEN1 (0.49) | MEN1KMT2AASAH1PSMB5CETP | |
| SCHEMBL15617050 | 0.81 | PAX8 (0.41) | CYP2C9MEN1KMT2AASAH1PSMB5 | |
| SCHEMBL25159573 | 0.80 | PAX8 (0.36) | MEN1KMT2AASAH1CETPTHRB | |
| SCHEMBL14902203 | 0.80 | MEN1 (0.35) | MEN1KMT2AASAH1CETPTHRB | |
| SCHEMBL13501555 | 0.79 | MEN1 (0.58) | MEN1KMT2AASAH1PSMB5CETP | |
| SCHEMBL18842950 | 0.78 | MEN1 (0.49) | CYP2C9MEN1KMT2AASAH1PSMB5 | |
| SCHEMBL4330718 | 0.78 | CNR1 (0.36) | MEN1KMT2AASAH1CNR1PAX8 | |
| SCHEMBL18842957 | 0.77 | MEN1 (0.44) | CYP2C9MEN1KMT2AASAH1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230379796-A1 | Processes for Preparing a MDM2 Inhibitor | AMGEN INC. | 2023-11-23 | — | — | US | disclosed |
| US-11753386-B2 | Processes for preparing a MDM2 inhibitor | AMGEN, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210347743-A1 | Processes for Preparing a MDM2 Inhibitor | AMGEN INC. | 2021-11-11 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | CYP2C9 1076/4885MEN1 4525/4885KMT2A 1751/4885 |
| US-20210347743-A1 | Processes for Preparing a MDM2 Inhibitor | MDM2, TP53, SKP2 | CYP2C9 1515/4885MEN1 1803/4885KMT2A 1036/4885 |
| US-11753386-B2 | Processes for preparing a MDM2 inhibitor | MDM2, TP53, SKP2 | CYP2C9 1515/4885MEN1 1803/4885KMT2A 1036/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | CYP2C9 1752/4885MEN1 4530/4885KMT2A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.